RxDoctor Payments Data

Ryan Maves, MD

Infectious Disease · Winston Salem, NCNPI 1407826670

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $35,310 of the $40,390 with a category attached, or 87.4%. 8 manufacturers reported payments, led by Shionogi Inc at 52.0% of the total. Reporting peaked in 2024 at $18,523 and has fallen 50.7% since, to $9,140 in 2025. Among infectious disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,390in general payments, 2019–2025

Across 37 payments — averaging $1091.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$21K
  • GSK$17K
  • EMD Serono, Inc.$2K
  • Abiomed$295
  • Merck$183
  • Paratek Pharmaceuticals, Inc.$151
  • plus $171 from 2 others
$44,674in research payments, 2019–2025

Across 5 payments — averaging $8934.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$24K
  • Merck$21K

What the payments were for

  • Consulting fees$35,31087%
  • Speaking & faculty fees$1500%
  • Travel & lodging$1,1003%
  • Food & beverage$3,7279%
  • Education$1020%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Shionogi Inc20$20,990
GSK2$16,900
EMD Serono, Inc.1$1,700
Abiomed3$295
Merck5$183
Paratek Pharmaceuticals, Inc.3$151
AstraZeneca1$150
Cvrx, Inc.2$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,390 in reported general payments places this provider in the 90th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$38,864
Medicare patients
114
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala14$54,622
Posaconazole13$31,854
Voriconazole12$3,905
Methenamine Hippurate39$2,629
Ethambutol Hcl17$1,283
Fluconazole25$1,056
Doxycycline Hyclate11$495
Ivermectin12$441
Azithromycin13$433

Paid to pharmacies, not to this prescriber.

Other infectious disease in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →